The active ingredient in Taltz, ixekizumab, is a monoclonal antibody that works by inhibiting the inflammatory response in adults with plaque psoriasis, active psoriatic arthritis, active ankylosing spondylitis, and non-radiographic axial spondyloarthritis.

Taltz selectively binds with interleukin 17A (IL-17A) cytokine, a naturally occurring substance that can cause inflammation. Taltz inhibits the release of pro-inflammatory cytokines and chemokines by inhibiting the interaction of IL-17A with the IL-17 receptor.

Taltz affects the immune system. It may increase the risk of infections, which can be serious. Taltz should not be used in patients who have any symptoms of infection, unless a doctor advises otherwise.